Rocket Pharmaceuticals, Inc. (NASDAQ: RCKT) is a Healthcare company (Biotechnology) with a market capitalization of $236M. The Maz Rating grades it against the other companies in its sector.
Rocket Pharmaceuticals, Inc.'s current Maz Rating and its five factor grades are for members: log in to see them.
At $2.11, Rocket Pharmaceuticals, Inc. trades at 0.7x book value, with an EV/EBITDA of 34.0. It runs a gross margin of 0.0%, an operating margin of 0.0% and a net margin of 0.0%. It shows return on equity of -5.3%, return on invested capital of -49.6% and a free cash flow yield of -67.6%. On the balance sheet: a debt-to-equity ratio of 0.17 and a current ratio of 7.26. Over the past 52 weeks the share price ranged from $2.03 to $5.45, with a beta of 0.49.
Rocket Pharmaceuticals, Inc. does not currently pay a dividend.
19 Wall Street analyst ratings cover the stock: 14 Buy, 4 Hold and 1 Sell, for a Buy consensus. This is the sell side's view, separate from the Maz Rating.
Rocket Pharmaceuticals, Inc., operating alongside its affiliates, is an innovative biotechnology enterprise dedicated to pioneering gene therapies for rare and severely debilitating diseases. The company's active clinical pipeline features multiple promising programs. It is currently progressing three ex vivo lentiviral vector therapies aimed at specific genetic conditions: Fanconi anemia, characterized by a bone marrow defect that hinders blood cell production; leukocyte adhesion deficiency-I, an inherited disorder resulting in a compromised immune system; and pyruvate kinase deficiency, a rare autosomal recessive red blood cell ailment leading to chronic non-spherocytic hemolytic anemia. Complementing these, Rocket Pharmaceuticals also has an in vivo adeno-associated virus program underway for Danon disease, a serious multi-organ lysosomal storage disorder that tragically often results in early mortality due to heart failure. To facilitate its extensive research and development efforts, the company has established key licensing partnerships with esteemed institutions such as the Fred Hutchinson Cancer Research Center, European research bodies including CIEMAT and its collaborators (Centro de Investigacion Biomedica En Red and Fundacion Instituto de investigacion Sanitaria Fundacion Jimenez Diaz), UCL Business PLC (in conjunction with CIEMAT), The Regents of the University of California, and REGENXBIO, Inc. Rocket Pharmaceuticals, Inc. maintains its primary corporate location in Cranbury, New Jersey.
Figures are trailing twelve months unless stated. The Maz Rating and Maz Dividend Score rank a company against its own sector; they are not price targets or recommendations.
No. As of September 2026, Rocket Pharmaceuticals, Inc. (RCKT) is classified as NOT HALAL by Maz Vantage: it fails every published Shariah screening standard it could be measured against (AAOIFI, S&P Global, Dow Jones, MSCI and FTSE).
| Standard | Ratios (value / limit) | Result |
|---|---|---|
| AAOIFI | Debt / Mkt Cap (36m) 9.32% / 30% · (Cash+Inv) / Mkt Cap (36m) 85.6% / 30% · Interest income / Revenue 101400000.0% / 5% | Fail |
| S&P Global | Debt / Mkt Cap (36m) 9.32% / 33% · (Cash+ST Inv) / Mkt Cap (36m) 82.5% / 33% · Receivables / Mkt Cap (36m) 0.00% / 49% · Interest income / Revenue 101400000.0% / 5% | Fail |
| Dow Jones | Debt / Mkt Cap (24m) 9.32% / 33.33% · (Cash+ST Inv) / Mkt Cap (24m) 82.5% / 33.33% · Receivables / Mkt Cap (24m) 0.00% / 33.33% · Interest income / Revenue 101400000.0% / 5% | Fail |
| MSCI | Debt / Avg Assets (4Q) 2.09% / 33.33% · (Cash+ST Inv) / Avg Assets (4Q) 60.8% / 33.33% · Receivables / Avg Assets (4Q) 0.00% / 33.33% · Interest income / Revenue 101400000.0% / 5% | Fail |
| FTSE | Debt / Total Assets 7.25% / 33.33% · (Cash+ST Inv) / Total Assets 64.2% / 33.33% · (Cash+Recv) / Total Assets 64.2% / 33.33% · Interest income / Revenue 101400000.0% / 5% | Fail |
No. As of September 2026, Rocket Pharmaceuticals, Inc. (RCKT) is classified as NOT HALAL by Maz Vantage: it fails every published Shariah screening standard it could be measured against (AAOIFI, S&P Global, Dow Jones, MSCI and FTSE).
No. Rocket Pharmaceuticals, Inc. is over the AAOIFI limit on (Cash+Inv) / Mkt Cap (36m) and Interest income / Revenue.
About 101400000.0% of each dividend: Rocket Pharmaceuticals, Inc.'s interest income as a share of its revenue. Give that share to charity; the dividend purification calculator works it out per holding.
The screen is rerun on each quarterly report; the figures here are from the balance sheet dated September 30, 2026 (Q3 2026). A status can change from one quarter to the next as debt, cash and market value move.
See also the list of halal stocks, halal healthcare stocks, the halal stock screener, the dividend purification calculator and the zakat calculator.
A mechanical screen of published financial ratios and the company's line of business, not a religious ruling. It does not test every revenue stream; check with a scholar you trust.